These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15477422)

  • 1. Prevention of sudden death in hypertrophic cardiomyopathy: but which defibrillator for which patient?
    Boriani G; Maron BJ; Shen WK; Spirito P
    Circulation; 2004 Oct; 110(15):e438-42. PubMed ID: 15477422
    [No Abstract]   [Full Text] [Related]  

  • 2. [Alcohol septal ablation and prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. A case report].
    Ardashev AV; Shavarov AA; Dzhandzhgava AO; Rybachenko MS; Kriuchko MIu
    Kardiologiia; 2009; 49(6):72-9. PubMed ID: 19656099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sudden cardiac death in familial hypertrophic cardiomyopathy. Identification of high-risk patients].
    Pellnitz C; Geier C; Perrot A; Dietz R; Osterziel KJ; Haverkamp W
    Dtsch Med Wochenschr; 2005 May; 130(18):1150-4. PubMed ID: 15856398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of hypertrophic cardiomyopathy.
    Enriquez AD; Goldman ME
    Ann Glob Health; 2014; 80(1):35-45. PubMed ID: 24751563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple type of obstruction in hypertrophic cardiomyopathy.
    Efthimiadis GK; Parcharidou DG; Vassilikos V; Giannakoulas G; Pliakos C; Parcharidis GE
    J Cardiovasc Med (Hagerstown); 2008 Nov; 9(11):1156-8. PubMed ID: 18852593
    [No Abstract]   [Full Text] [Related]  

  • 6. The ICD for primary prevention in patients with inherited cardiac diseases: indications, use, and outcome: a comparison with secondary prevention.
    Olde Nordkamp LR; Wilde AA; Tijssen JG; Knops RE; van Dessel PF; de Groot JR
    Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):91-100. PubMed ID: 23275262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
    N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive risk stratification prevents sudden death due to paroxysmal atrial fibrillation in hypertrophic cardiomyopathy.
    Limongelli G; Elliott PM; Pacileo G; Sarubbi B; Thaman R; Calabrò P; Vergara P; Iacomino M; Russo MG; Calabrò R
    J Cardiovasc Med (Hagerstown); 2006 Sep; 7(9):711-3. PubMed ID: 16932087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TED-Time and life saving External Defibrillator for home-use.
    Weiss TA; Rosenheck S; Gorni S; Katz I; Mendelbaum M; Gilon D
    Cardiovasc Revasc Med; 2014 Jun; 15(4):233-4. PubMed ID: 24721586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolution and revolution of the implantable cardioverter defibrillator.
    Indik JH
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):461-4. PubMed ID: 15225105
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to effectiveness and cost-effectiveness of public access automatic defibrillator (AED) programs.
    McGuire-Wolfe C
    Clin Cardiol; 2011 Jan; 34(1):64; author reply 64. PubMed ID: 21259281
    [No Abstract]   [Full Text] [Related]  

  • 12. Extreme septal hypertrophy in an adolescent with congenital familial hypertrophic cardiomyopathy.
    Park BW; Lee MH; Bang DW; Hyon MS
    Korean J Intern Med; 2015 Nov; 30(6):940-1. PubMed ID: 26552475
    [No Abstract]   [Full Text] [Related]  

  • 13. [Sudden death: heart defibrillator as guardian angel].
    Derrien E
    Rev Infirm; 2004 Mar; (99):23-4. PubMed ID: 15124490
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy.
    Maron MS; Olivotto I; Betocchi S; Casey SA; Lesser JR; Losi MA; Cecchi F; Maron BJ
    N Engl J Med; 2003 Jan; 348(4):295-303. PubMed ID: 12540642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. My approach to clinical management of hypertrophic cardiomyopathy.
    Maron MS
    Trends Cardiovasc Med; 2014 Oct; 24(7):314-5. PubMed ID: 25218674
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevention of sudden cardiac deaths in arrhythmogenic right ventricular cardiomyopathy: how to evaluate risk and when to implant a cardioverter-defibrillator?
    Woźniak O; Włodarska EK
    Cardiol J; 2009; 16(6):588-91. PubMed ID: 19950101
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk and Causes of Death in Patients After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy.
    Veselka J; Zemánek D; Jahnlová D; Krejčí J; Januška J; Dabrowski M; Bartel T; Tomašov P
    Can J Cardiol; 2015 Oct; 31(10):1245-51. PubMed ID: 26095933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Athletes with implantable cardioverter defibrillators: can they return to competitive sports?
    Prutkin JM; Ackerman MJ; Drezner JA
    Heart; 2016 Jan; 102(2):93-4. PubMed ID: 26729607
    [No Abstract]   [Full Text] [Related]  

  • 19. The dilemma of left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy: do patients with gradients really deserve prophylactic defibrillators?
    Maron BJ; Olivotto I; Maron MS
    Eur Heart J; 2006 Aug; 27(16):1895-7. PubMed ID: 16818455
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiology patient page. Hypertrophic cardiomyopathy: a patient perspective.
    Nishimura RA; Ommen SR; Tajik AJ
    Circulation; 2003 Nov; 108(19):e133-5. PubMed ID: 14609998
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.